1 DNA Way
South San Francisco
About Genentech, Inc.
Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.
On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.
Connect with us via Social Media:
CEO: Ian T. Clark
CEO: Ed Harrington
Chief Medical Officer: Sandra J. Horning, MD
Chief Compliance Officer: Frederick C. Kentz, III
Please click here for clinical trial information.
Living 10 Years in the Future
1052 articles with Genentech, Inc.
Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Venclexta represents a potential new way of treating AML, the most common type of aggressive leukemia in adults
This is a co-formulation with Halozyme's proprietary recombinant human hyaluronidase enzyme, which is approved and marketed under the Herceptin® SC brand in many countries outside the U.S.
Changes continue coming to Vivek Ramaswamy’s Roivant Sciences following a June shakeup that saw a 10 percent cut in employment and the restructuring of its business operations.
Orchard Therapeutics, today announced the appointment of Joanne Beck, Ph.D., to its board of directors.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.
Miracles, it seems, have a high price tag. At least, if those miracles are miracle drugs. There’s no doubt that trends in gene therapy and immuno-oncology are producing drugs that are as close to miraculous as we’re likely to get, doing a great job, generally, in beating back diseases that to thi...
Phase III IMpassion130 Study Showed Genentech’s TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
First Phase III immunotherapy study to demonstrate a statistically significant progression-free survival (PFS) improvement in intention-to-treat (ITT) and PD-L1 positive first-line metastatic triple negative breast cancer (TNBC) populations
Cambridge, Massachusetts-based Biogen exercised its option to acquire additional shares of Samsung Bioepis, a joint venture with Samsung BioLogics that was founded in 2012.
With increased worries over the addictive nature of opioid-based pain treatments, more and more companies are focusing on the development of effective treatments without the addictive nature.
Influenza, or “flu,” represents a serious threat to public health – globally, annual epidemics result in 3 to 5 million cases of severe disease, millions of hospitalizations and up to 650,000 deaths worldwide
The FDA accepted Genentech’s New Drug Application (NDA) for baloxavir marboxil, a single-dose, oral flu treatment for people 12 years and older. It also granted it Priority Review.
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
From CRISPR to spider silk there are some great scientific research stories out this week.
Genentech Announces New OCREVUS (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of Two Global Studies in Progressive MS
Genentech announced today that new OCREVUS® (ocrelizumab) data will be presented at the 4th Congress of the European Academy of Neurology.
FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab).
CORRECTING and REPLACING FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery
Avastin is now approved for ten distinct uses across six different types of cancer in the United States
Cell Medica today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Company’s Board of Directors.
Aimmune Therapeutics, Inc. today announced the appointment of Jayson Dallas, M.D., as President and Chief Executive Officer.
Genentech Announces FDA Approval for Venclexta Plus Rituxan for People with Previously Treated Chronic Lymphocytic Leukemia
Genentech announced today that the U.S. Food and Drug Administration (FDA) has approved Venclexta® in combination with Rituxan® for the treatment of people with chronic lymphocytic leukemia or small lymphocytic lymphoma.